Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

809 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PD-1 Blockade in Anaplastic Thyroid Carcinoma.
Capdevila J, Wirth LJ, Ernst T, Ponce Aix S, Lin CC, Ramlau R, Butler MO, Delord JP, Gelderblom H, Ascierto PA, Fasolo A, Führer D, Hütter-Krönke ML, Forde PM, Wrona A, Santoro A, Sadow PM, Szpakowski S, Wu H, Bostel G, Faris J, Cameron S, Varga A, Taylor M. Capdevila J, et al. Among authors: varga a. J Clin Oncol. 2020 Aug 10;38(23):2620-2627. doi: 10.1200/JCO.19.02727. Epub 2020 May 4. J Clin Oncol. 2020. PMID: 32364844 Free PMC article. Clinical Trial.
Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer.
Martin-Romano P, Ammari S, El-Dakdoukti Y, Baldini C, Varga A, Vuagnat P, Angevin E, Bahleda R, Gazzah A, Champiat S, Michot JM, Postel-Vinay S, Marabelle A, Soria JC, Boige V, Malka D, Ducreux M, Massard C, Hollebecque A. Martin-Romano P, et al. Among authors: varga a. Eur J Cancer. 2020 Sep;137:117-126. doi: 10.1016/j.ejca.2020.06.030. Epub 2020 Aug 2. Eur J Cancer. 2020. PMID: 32755794
Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors.
Bahleda R, Le Deley MC, Bernard A, Chaturvedi S, Hanley M, Poterie A, Gazzah A, Varga A, Touat M, Deutsch E, Massard C, Van De Velde H, Hollebecque A, Sallansonnet-Froment M, Ricard D, Taillia H, Angevin E, Ribrag V, Soria JC. Bahleda R, et al. Among authors: varga a. Invest New Drugs. 2018 Aug;36(4):619-628. doi: 10.1007/s10637-017-0531-3. Epub 2017 Nov 2. Invest New Drugs. 2018. PMID: 29094232 Clinical Trial.
Safety of osimertinib in EGFR-mutated non-small cell lung cancer.
Mezquita L, Varga A, Planchard D. Mezquita L, et al. Among authors: varga a. Expert Opin Drug Saf. 2018 Dec;17(12):1239-1248. doi: 10.1080/14740338.2018.1549222. Epub 2018 Dec 5. Expert Opin Drug Saf. 2018. PMID: 30457891 Review.
Immunothérapie des glioblastomes.
Baldini C, Romano PM, Varga A, Champiat S, Dumont S, Dhermain F, Louvel G, Marabelle A, Postel-Vinay S, Angevin E, Gazzah A, Ribrag V, Bahleda R, Michot JM, Hollebecque A, Soria JC, Massard C. Baldini C, et al. Among authors: varga a. Bull Cancer. 2018 Dec;105 Suppl 1:S59-S67. doi: 10.1016/S0007-4551(18)30391-6. Bull Cancer. 2018. PMID: 30595200 Review. French.
Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies.
Baldini C, Martin Romano P, Voisin AL, Danlos FX, Champiat S, Laghouati S, Kfoury M, Vincent H, Postel-Vinay S, Varga A, Vuagnat P, Ribrag V, Mezquita L, Besse B, Hollebecque A, Lambotte O, Michot JM, Soria JC, Massard C, Marabelle A. Baldini C, et al. Among authors: varga a. Eur J Cancer. 2020 Apr;129:71-79. doi: 10.1016/j.ejca.2020.01.013. Epub 2020 Mar 3. Eur J Cancer. 2020. PMID: 32143106
Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers.
Baldini C, Danlos FX, Varga A, Texier M, Halse H, Mouraud S, Cassard L, Champiat S, Signolle N, Vuagnat P, Martin-Romano P, Michot JM, Bahleda R, Gazzah A, Boselli L, Bredel D, Grivel J, Mohamed-Djalim C, Escriou G, Grynszpan L, Bigorgne A, Rafie S, Abbassi A, Ribrag V, Postel-Vinay S, Hollebecque A, Susini S, Farhane S, Lacroix L, Parpaleix A, Laghouati S, Zitvogel L, Adam J, Chaput N, Soria JC, Massard C, Marabelle A. Baldini C, et al. Among authors: varga a. J Exp Clin Cancer Res. 2022 Jul 7;41(1):217. doi: 10.1186/s13046-022-02423-0. J Exp Clin Cancer Res. 2022. PMID: 35794623 Free PMC article. Clinical Trial.
Genome-driven medicine for patients with recurrent glioma enrolled in early phase trials.
Baldini C, Younan N, Castanon Alvarez E, Ammari S, Alentorn A, Dumont S, Frenel JS, Di Stefano AL, Louvel G, Michot JM, Bahleda R, Postel-Vinay S, Varga A, Marabelle A, Hollebecque A, Bielle F, Hoang-Xuan K, Delattre JY, Dhermain F, Sanson M, Soria JC, Idbaih A, Massard C, Touat M. Baldini C, et al. Among authors: varga a. Eur J Cancer. 2022 Mar;163:98-107. doi: 10.1016/j.ejca.2021.11.017. Epub 2022 Jan 18. Eur J Cancer. 2022. PMID: 35063776
Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI Score.
Pierro M, Baldini C, Auclin E, Vincent H, Varga A, Martin Romano P, Vuagnat P, Besse B, Planchard D, Hollebecque A, Champiat S, Marabelle A, Michot JM, Massard C, Mezquita L. Pierro M, et al. Among authors: varga a. Cancers (Basel). 2022 Oct 17;14(20):5078. doi: 10.3390/cancers14205078. Cancers (Basel). 2022. PMID: 36291861 Free PMC article.
[Focus on targeting the Ras-MAPK pathway: the Mek inhibitors].
Baldini C, Duchemann B, Hollebecque A, Routier É, Varga A, Gazzah A, Bahleda R, Besse B, Soria JC, Massard C. Baldini C, et al. Among authors: varga a. Bull Cancer. 2012 Sep;99(9):865-74. doi: 10.1684/bdc.2012.1632. Bull Cancer. 2012. PMID: 25471668 Free article. Review. French.
809 results